Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis
Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis
复制标题
DOI：
10.1093/annonc/mdn639
复制
发表时间：
2009-03-01
影响因子：
50.5
通讯作者：
Brenner, H.
中科院分区：
文献类型：
--
作者：
Gondos, A.;Bray, F.;Brenner, H.
背景资料：及时提供和解释基于人群的癌症生存率估计的趋势是临床和公共卫生的重要优先事项。材料和方法：我们研究了1990-1994年和2000-2004年欧洲不同地区10个国家15种常见癌症的生存趋势，并提供了2005-2009年的预测生存估计，使用基于模型的周期分析的新技术。结果：在1990-1994年和2000-2004年之间，在所有参与的登记研究中，前列腺癌、乳腺癌和结直肠癌患者的5年相对生存率显著增加，在11个登记研究中，至少有7个登记研究的胃癌、子宫体癌、卵巢癌、肾癌和甲状腺癌，以及非霍奇金淋巴瘤。预测表明，在2005-2009年日历期间，存活率将进一步大幅提高。对于大多数癌症网站适合有效的早期检测和治疗，主要的地理差异持续存在较低的生存率在东欧countries.Conclusions：基于模型的时期分析可能是有用的，在提供基于人口的癌症生存估计目前诊断的癌症患者。在癌症护理的组织和质量控制方面的协调努力对于进一步改善欧洲的癌症控制非常重要，改善东欧人群的结果仍然是一个优先事项。
Background: The timely provision and interpretation of trends in population-based cancer survival estimates is an important clinical and public health priority.Materials and methods: We examined survival trends between 1990-1994 and 2000-2004 for 15 common cancers in 10 countries from diverse areas of Europe and provide projected survival estimates for 2005-2009, using novel techniques of model-based period analysis.Results: Between 1990-1994 and 2000-2004, the 5-year relative survival increased significantly in all participating registries among patients with prostate, breast, and colorectal cancers and in at least 7 of 11 registries for stomach, corpus uteri, ovarian, kidney, and thyroid cancers, as well as for non-Hodgkin's lymphoma. Projections suggest further substantial increases in survival in the calendar period 2005-2009. For most cancer sites amenable to effective early detection and treatment, major geographical differences persist with lower survival in Eastern European countries.Conclusions: Model-based period analysis may be useful in providing population-based cancer survival estimates for currently diagnosed cancer patients. Concerted efforts in the organisation and quality control of cancer care will be very important to achieving further improvements in cancer control in Europe, and improving outcomes in Eastern European populations remains a priority.